HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, New York, NY, USA.
HIV Center for Clinical and Behavioral Studies, Unit 15, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA.
AIDS Behav. 2018 Feb;22(2):388-401. doi: 10.1007/s10461-017-1890-7.
Adherence to product use in biomedical HIV prevention trials is essential to success. In MTN-017, a Phase 2 rectal microbicide gel trial, participants discussed applicator-inserted gel use in the context of receptive anal intercourse (RAI) with adherence counselors. We analyzed counseling session data to identify barriers to and facilitators of gel use for 26 participants in the United States who used gel with RAI as their first of three study regimens. The most common barriers were finding the gel application process cumbersome, physical discomfort after applying gel, difficulty with BAT-24 dosage regimen, and negative effects of gel on sex. The most common facilitators were incorporating gel use into routines, using gel in anticipation of sex, carrying gel when going out, reminders received via short message service, and ease of gel use. These findings can inform product development and future adherence counseling interventions for rectal gel trials to improve adherence outcomes.
在生物医学 HIV 预防试验中，坚持使用产品对于成功至关重要。在 MTN-017 二期直肠用杀微生物剂凝胶试验中，参与者与坚持使用顾问讨论了在接受性肛交（RAI）情况下使用插入式给药器给药的凝胶。我们分析了咨询会议数据，以确定 26 名美国参与者在三种研究方案中首次使用凝胶与 RAI 同时使用时，使用凝胶的障碍和促进因素。最常见的障碍是发现凝胶使用过程繁琐、使用凝胶后身体不适、难以遵循 BAT-24 剂量方案以及凝胶对性行为的负面影响。最常见的促进因素是将凝胶使用纳入日常生活、在预期性行为时使用凝胶、外出时携带凝胶、收到短信服务提醒以及凝胶使用方便。这些发现可以为直肠凝胶试验的产品开发和未来的坚持使用咨询干预措施提供信息，以改善坚持使用的结果。
